论文部分内容阅读
近年来,全球肝病无创诊断取得突破性进展,由内蒙古福瑞医疗科技股份有限公司控股子公司——法国爱科森医疗科技有限公司(ECHOSENS)开发的FibroScan器械是其中突出的代表,目前全球已有87个国家的近3000家医院在临床使用。FibroScan适用于各种慢性肝病包括病毒性肝炎、酒精性肝炎及自身免疫性肝病等所导致的肝纤维化、肝硬化、脂肪肝的检查,是目前全球唯一可实现对肝脏硬度及脂肪变进行无创定量检测的设备,大大提高了患者肝纤维化、肝硬化、
In recent years, breakthroughs have been made in the noninvasive diagnosis of liver diseases worldwide. The FibroScan instrument developed by ECHOSENS, a subsidiary of Inner Mongolia Furui Medical Technology Co., Ltd., is a prominent representative. At present, Nearly 3,000 hospitals in 87 countries are in clinical use. FibroScan is suitable for all kinds of chronic liver diseases including viral hepatitis, alcoholic hepatitis and autoimmune liver disease caused by liver fibrosis, cirrhosis, fatty liver examination, is currently the world’s only non-invasive liver hardness and steatosis can be achieved Quantitative testing equipment, greatly improving patients with liver fibrosis, cirrhosis,